Results 41 to 50 of about 32,321 (308)
Access to Biobanks: Harmonization Across Biobank Initiatives [PDF]
Biopreservation and Biobanking, 2014 The current study investigates whether access arrangements relevant for biobanking contain clear information on key access conditions. It furthermore assesses the extent to which these access conditions are harmonized across biobank initiatives.A comparative analysis was conducted of access arrangements developed by 26 organizations, 36 biobank ...
Michiel, Verlinden +3 more
openaire +3 more sources
Integrating population-based biobanks: Catalyst for advances in precision health
Computational and Structural Biotechnology JournalPrecision health extends beyond the scope of precision medicine and involves a broader range of activities, including the prediction, prevention, treatment, and management of diseases.
Jui-Chu Lin +3 more
doaj +1 more source
From pharmacogenetics to pharmaco-omics: Milestones and future directions
HGG Advances, 2022 The origins of pharmacogenetics date back to the 1950s, when it was established that inter-individual differences in drug response are partially determined by genetic factors.
Chiara Auwerx +3 more
doaj +1 more source
, 2016 Biobanks, which contain human biological samples and/or data, provide a crucial contribution to the progress of biomedical research. However, the effective and efficient use of biobank resources depends on their accessibility.
Anagnostou, Paolo +6 more
core +1 more source
Pediatric Blood &Cancer, EarlyView.ABSTRACT Background An internal tandem duplication in the gene encoding Fms‐like tyrosine kinase 3 (FLT3‐ITD) is associated with high relapse risk and poor prognosis in acute myeloid leukemia (AML) and plays a crucial role in treatment decisions. Measurable residual disease (MRD) analysis of FLT3‐ITD during and after treatment has shown prognostic ...
Sofie Johansson Alm +11 more
wiley +1 more source
Clinical trials and the importance of biobanks in rare diseases [PDF]
Scripta Medica, 2018 Rare diseases ('orphan diseases') (RDs) count for 5000-8000 diseases with low prevalence and most commonly of genetic origin. Although most of rare diseases are manifested in early childhood, many are diagnosed in adults, even in elderly.
Nežić Lana +3 more
doaj
The UK National Health Service’s 'innovation agenda': lessons on commercialization and trust [PDF]
, 2014 The UK National Health Service (the 'NHS'), encouraged by the 2011 report Innovation Health and Wealth, Accelerating Adoption and Diffusion in the NHS, and empowered by the Health and Social Care Act 2012, is in the process of adopting a new agenda for ...
Cockbain, Julian, Sterckx, Sigrid
core +2 more sources
Organoids in pediatric cancer research
FEBS Letters, EarlyView.Organoid technology has revolutionized cancer research, yet its application in pediatric oncology remains limited. Recent advances have enabled the development of pediatric tumor organoids, offering new insights into disease biology, treatment response, and interactions with the tumor microenvironment.
Carla Ríos Arceo, Jarno Drost
wiley +1 more source
Setting up clinical and production-based biobanks in the healthcare system of the Russian Federation
Трансплантология (Москва)Background. The therapeutic efficacy of skin grafts and various tissue equivalents in the treatment of many diseases is known. Special clinical biobanks are engaged in the procurement of such products, their processing, storage, provision of their safety
Yu. N. Lebedeva +7 more
doaj +1 more source
Diversity and complexity in neural organoids
FEBS Letters, EarlyView.Neural organoid research aims to expand genetic diversity on one side and increase tissue complexity on the other. Chimeroids integrate multiple donor genomes within single organoids. Self‐organising multi‐identity organoids, exogenous cell seeding, or enforced assembly of region‐specific organoids contribute to tissue complexity.
Ilaria Chiaradia, Madeline A. Lancaster
wiley +1 more source